Theravance Biopharma Inc TBPH.OQ TBPH.O is expected to show a fall in quarterly revenue when it reports results on February 26 for the period ending December 31 2024
The George Town Grand Cayman-based company is expected to report a 2.7% decrease in revenue to $17.091 million from $17.57 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Theravance Biopharma Inc is for a loss of 21 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Theravance Biopharma Inc is $12.50, above its last closing price of $9.32.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.24 | -0.23 | -0.26 | Missed | -12.6 |
Jun. 30 2024 | -0.22 | -0.21 | -0.28 | Missed | -35.6 |
Mar. 31 2024 | -0.22 | -0.25 | -0.24 | Beat | 5.5 |
Dec. 31 2023 | -0.17 | -0.15 | -0.17 | Missed | -14.3 |
Sep. 30 2023 | -0.22 | -0.21 | -0.17 | Beat | 18.9 |
Jun. 30 2023 | -0.22 | -0.21 | -0.28 | Missed | -33.3 |
Mar. 31 2023 | -0.25 | -0.25 | -0.35 | Missed | -42.1 |
Dec. 31 2022 | -0.17 | -0.17 | -0.15 | Beat | 13 |
This summary was machine generated February 24 at 21:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)